Ferroptosis Therapy for Parkinson's Disease

📖 Wiki Page

therapeutic2005 wordssynced 2026-04-02

Ferroptosis Therapy for Parkinson's Disease

...

Ferroptosis Therapy for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Ferroptosis Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Deferoxamine (DFO)</td>
<td>Binds Fe3+; limited BBB penetration</td>
</tr>
<tr>
<td class="label">Deferasirox</td>
<td>Oral iron chelator; moderate BBB penetration</td>
</tr>
<tr>
<td class="label">Deferiprone</td>
<td>Brain-penetrant chelator; crosses BBB</td>
</tr>
<tr>
<td class="label">Clioquinol</td>
<td>Metal-protein attenuating compound</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT01416064</td>
<td>Deferoxamine</td>
</tr>
<tr>
<td class="label">FAIRPARK-II</td>
<td>Deferiprone</td>
</tr>
<tr>
<td class="label">NCT04833351</td>
<td>Deferasirox</td>
</tr>
<tr>
<td class="label">NCT03764280</td>
<td>Alpha-tocopherol</td>
</tr>
<tr>
<td class="label">NCT06012382</td>
<td>Sulforahane</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">Ferritin</td>
<td>Serum, CSF</td>
</tr>
<tr>
<td class="label">Transferrin</td>
<td>Serum</td>
</tr>
<tr>
<td class="label">4-HNE</td>
<td>CSF, tissue</td>
</tr>
<tr>
<td class="label">F2-isoprostanes</td>
<td>CSF, urine</td>
</tr>
<tr>
<td class="label">GPX4 activity</td>
<td>PBMCs</td>
</tr>
<tr>
<td class="label">Iron (Fe)</td>
<td>Serum, CSF</td>
</tr>
<tr>
<td class="label">MDA</td>
<td>Serum</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Deferiprone + NAC</td>
<td>Iron chelation + GSH support</td>
</tr>
<tr>
<td class="label">Ferrostatin-1 + Vitamin E</td>
<td>Dual lipid antioxidant pathways</td>
</tr>
<tr>
<td class="label">Nrf2 activator + Iron chelation</td>
<td>Antioxidant + iron reduction</td>
</tr>
<tr>
<td class="label">Selegiline + Ferroptosis inhibitor</td>
<td>MAO-B inhibition + neuroprotection</td>
</tr>
</table>

Therapeutic Category: Disease-Modifying Therapies | Neuroprotection Target: [Ferroptosis](/mechanisms/ferroptosis) pathway (GPX4, System Xc-, lipid peroxidation, iron metabolism) Indications: Parkinson's Disease, Parkinsonism Syndromes Status: Preclinical to Clinical (Phase 2)

Pathway Diagram

Mermaid diagram (expand to render)

Overview

Ferroptosis Therapy for Parkinson's Disease represents a targeted neuroprotective strategy specifically addressing the iron-dependent, lipid peroxidation-driven cell death pathway implicated in dopaminergic neuron loss. Unlike general neuroprotective approaches, this therapy directly targets the molecular mechanisms of ferroptosis: glutathione peroxidase 4 ([GPX4](/genes/gpx4)) dysfunction, [System Xc-](/proteins/slc7a11-protein) impairment, [ACSL4](/genes/acsl4) upregulation, and iron accumulation in the [substantia nigra](/brain-regions/substantia-nigra). [@li2024]

The rationale for ferroptosis-targeted therapy in PD stems from multiple converging lines of evidence: iron accumulation is a well-documented pathological hallmark of PD brains, lipid peroxidation markers are elevated in PD substantia nigra and cerebrospinal fluid, and GPX4 activity is compromised in PD models and patient tissue. [@zhang2024] This creates a "perfect storm" where dopaminergic neurons become exquisitely vulnerable to ferroptotic death.

Molecular Targets in Parkinson's Disease

GPX4 (Glutathione Peroxidase 4)

[GPX4](/proteins/gpx4) is the central regulator of ferroptosis and the primary therapeutic target in PD. Unlike other glutathione peroxidases, GPX4 directly reduces lipid hydroperoxides (LOOH) to corresponding alcohols (LOH), preventing iron-catalyzed lipid radical formation. In PD:

Expression reduction: GPX4 is downregulated in PD substantia nigra [@zhang2024]
Activity impairment: GPX4 enzymatic activity is reduced in PD models
Selenocysteine vulnerability: The selenocysteine at GPX4's active site makes it susceptible to oxidative damage

Therapeutic approaches to restore GPX4 function include:

Direct GPX4 activators (e.g., ML210 derivatives)
Selenoprotein synthesis enhancers (selenium supplementation)
GPX4 mimetics that replicate lipid peroxide reduction
N-acetylcysteine (NAC) to boost glutathione substrate availability

System Xc- (Cystine/Glutamate Antiporter)

The [System Xc-](/proteins/slc7a11-protein) (SLC7A11) is the cystine/glutamate antiporter that provides the cysteine substrate for glutathione synthesis. In PD:

Expression reduction: System Xc- expression is downregulated in PD models [@masaldan2023]
Function impairment: Cystine uptake is reduced, limiting glutathione synthesis
Dopaminergic neuron vulnerability: These neurons rely heavily on System Xc- for redox homeostasis

Therapeutic approaches:

N-acetylcysteine (NAC): Provides alternative cysteine source to bypass System Xc-
Buthionine sulfoximine (BSO): Inhibitor used in research to induce ferroptosis (not therapeutic)
Glutathione precursors: NAC, GSH esters

ACSL4 (Acyl-CoA Synthetase Long-Chain Family Member 4)

[ACSL4](/genes/acsl4) is an enzyme that incorporates long-chain polyunsaturated fatty acids into phospholipids, promoting lipid peroxidation. In PD:

Upregulation: ACSL4 is elevated in PD dopaminergic neurons [@chen2023]
Sensitivity driver: High ACSL4 expression sensitizes cells to ferroptosis
Therapeutic target: ACSL4 inhibition protects against ferroptotic death

Therapeutic approaches:

ACSL4 inhibitors: Development of small-molecule ACSL4 inhibitors
Dietary modification: Reducing dietary PUFA intake
Lipid metabolism modulators

FSP1 (Ferroptosis Suppressor Protein 1)

[FSP1](/genes/fsp1) (also known as AIFM2) is a coenzyme Q10-dependent ferroptosis suppressor that acts independently of GPX4. In PD:

Protective role: FSP1 reduces ubiquinone to ubiquinol, which directly traps lipid peroxyl radicals
Therapeutic potential: FSP1 activators could provide GPX4-independent neuroprotection [@zou2024]

[Nrf2](/proteins/nrf2) is the master regulator of antioxidant response. In PD:

Activation deficit: Nrf2 signaling is impaired in PD
Downstream targets: Nrf2 regulates GPX4, SLC7A11, ferritin, and heme oxygenase-1
Therapeutic target: Nrf2 activators can induce ferroptosis resistance genes [@cai2023]

Therapeutic Approaches

1. GPX4-Targeted Therapies

Direct GPX4 Activators

ML210: Covalent GPX4 activator in preclinical development
RSL3: GPX4 inhibitor (research tool, not therapeutic)
Diallyl trisulfide (DATS): Releases H2S and activates GPX4

GPX4 Substrate Enhancement

N-acetylcysteine (NAC): Glutathione precursor; improves GPX4 substrate availability
Glutathione ethyl ester: Cell-permeable GSH
Selenium supplementation: Supports selenocysteine incorporation into GPX4 [@conrad2016]

2. System Xc- Modulators

N-acetylcysteine (NAC): Bypasses System Xc- by providing alternative cysteine source
Glutathione esters: Cell-penetrating GSH derivatives
Dietary cystine: Increased dietary cystine intake

3. Direct Ferroptosis Inhibitors

Ferrostatins

Ferrostatin-1: Prototypical ferroptosis inhibitor; chain-breaking lipid antioxidant
Ferrostatin-2: Improved metabolic stability
Liproxstatin-1: Highly potent ferroptosis inhibitor [@skouta2014]

Mechanism

These compounds function as chain-breaking antioxidants that specifically trap lipid peroxyl radicals, preventing the propagation of lipid peroxidation. They are highly effective in preventing ferroptotic cell death in vitro and in vivo.

4. Lipid Metabolism Modulators

Vitamin E (α-tocopherol): Chain-breaking antioxidant; blocks lipid peroxidation propagation
ACSL4 inhibitors: Reduce PUFA incorporation into phospholipids
PUFA reduction: Dietary modification to reduce ferroptosis susceptibility

5. Iron Chelation

Iron chelation therapy is covered in detail on the [Iron Chelation Therapy for Parkinson's Disease](/therapeutics/iron-chelation-therapy-parkinsons-disease) page. Key agents include:

6. Nrf2 Activators

Sulforaphane: Potent Nrf2 activator; induces antioxidant response genes
Dimethyl fumarate (Tecfidera): FDA-approved Nrf2 activator
Bardoxolone methyl: Nrf2 activator in clinical trials for neurodegenerative diseases

Preclinical Evidence in Parkinson's Disease Models

In Vitro Evidence

GPX4 downregulation: GPX4 expression is reduced in PD patient-derived neurons and mouse models

Ferroptosis induction: Pharmacological GPX4 inhibition (RSL3) induces dopaminergic neuron death

Neuroprotection: Ferrostatin-1 and liproxstatin-1 protect dopaminergic neurons from ferroptotic death

Iron chelation: Deferoxamine and deferiprone reduce ferroptotic cell death in vitro

NAC efficacy: NAC protects against System Xc- inhibition-induced ferroptosis

In Vivo Evidence

Animal models: GPX4 knockout mice develop progressive neurodegeneration [@devos2014]

Iron chelation: Deferiprone reduces dopaminergic neuron loss in MPTP models

Ferrostatins: Lipophilic ferrostatins cross the BBB and protect against 6-OHDA toxicity

System Xc-: Genetic or pharmacological inhibition of System Xc- induces parkinsonian phenotype

ACSL4: ACSL4 knockout or inhibition protects against dopaminergic degeneration

Key Studies

[Li et al., Ferroptosis in Parkinson disease (Nat Rev Neurol, 2024)](https://pubmed.ncbi.nlm.nih.gov/39218077/)
[Zhang et al., GPX4 and ferroptosis in Parkinson's disease (J Neurochem, 2024)](https://doi.org/10.1111/jnc.16123)
[Ayton et al., Ferroptosis contributes to dopaminergic neuron loss (Brain, 2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)
[Do Van et al., Ferroptosis in Parkinson's disease (Mov Disord, 2016)](https://pubmed.ncbi.nlm.nih.gov/26671615/)

Clinical Trials in Parkinson's Disease

Completed and Active Trials

FAIRPARK-II Trial Results

The FAIRPARK-II trial (NCT02655333) evaluated deferiprone in 262 Parkinson's disease patients with motor complications: [@moreau2022]

Results:

Primary endpoint: Significant reduction in iron in the substantia nigra (R2* MRI)
Secondary endpoints: Mixed results on clinical outcomes (MDS-UPDRS)
Safety: Agranulocytosis monitoring required (serious adverse event management protocol)
Interpretation: Validated iron chelation as a disease-modifying approach; iron reduction achieved but clinical benefit uncertain

Ongoing Research

GPX4 activators: Preclinical development of brain-penetrant GPX4 direct activators
Ferrostatins: Optimization of pharmacokinetics for CNS penetration
Combination approaches: Iron chelation + ferroptosis inhibitors + standard of care
Biomarker development: Identifying patients most likely to benefit from ferroptosis-targeted therapy

Biomarkers for Patient Selection

Ferroptosis Biomarkers

Patient Selection Criteria

Elevated iron markers (serum ferritin, CSF iron)
Reduced GPX4 activity
High lipid peroxidation burden
Early disease stage (before extensive neuron loss)
MRI evidence of iron accumulation in substantia nigra

Combination Strategies

Rationale for Combination Therapy

Ferroptosis in PD involves multiple converging pathways. Targeting multiple mechanisms may provide synergistic benefit:

Iron chelation + ferroptosis inhibitors: Address iron accumulation AND lipid peroxidation

GPX4 activation + Nrf2 activation: Enhance both direct and indirect antioxidant capacity

System Xc- support + GSH precursor: Maximize glutathione availability

Standard of care + neuroprotection: Combine with dopaminergic therapies

Promising Combinations

Connected Mechanisms

[Oxidative Stress Response](/mechanisms/oxidative-stress): Ferroptosis is fundamentally an oxidative stress pathway
[Iron Metabolism](/mechanisms/iron-metabolism): Central to both normal neuronal function and ferroptosis
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction): Mitochondria are major sources of lipid peroxides
[Neuroinflammation](/mechanisms/neuroinflammation): Microglial activation can promote ferroptosis
[Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-pathology): Iron interacts with alpha-synuclein to promote aggregation

[Iron Chelation Therapy for Parkinson's Disease](/therapeutics/iron-chelation-therapy-parkinsons-disease)
[Ferroptosis Modulation Therapy](/therapeutics/ferroptosis-modulation-therapy) (general)
[Ferroptosis in Parkinson's Disease](/mechanisms/ferroptosis-parkinsons) (mechanism)
[Nrf2 Activators for Parkinson's Disease](/therapeutics/nrf2-activators-parkinsons-disease)
[CoQ10 for Parkinson's Disease](/therapeutics/coq10-parkinsons-disease)
[Neuroprotection](/therapeutics/neuroprotection)

[GPX4](/genes/gpx4)
[SLC7A11 (System Xc-)](/genes/slc7a11)
[ACSL4](/genes/acsl4)
[FSP1](/genes/fsp1)
[Nrf2](/proteins/nrf2)
[Ferritin](/proteins/ferritin-h)

Challenges and Future Directions

Current Limitations

BBB penetration: Many ferroptosis inhibitors (e.g., ferrostatin-1) have limited CNS exposure

Biomarker validation: No validated ferroptosis biomarkers for patient selection

Optimal timing: Unknown when in disease course ferroptosis-targeted therapy is most effective

Combination optimization: Unknown best combination strategy

Safety monitoring: Iron chelation requires careful monitoring (agranulocytosis, organ toxicity)

Emerging Strategies

Brain-penetrant ferrostatins: Next-generation ferrostatins with improved pharmacokinetics

Gene therapy: AAV-mediated GPX4 or FSP1 expression

Targeted delivery: Nanoparticle-based delivery of ferroptosis inhibitors

Personalized medicine: Genotype-guided ferroptosis modulation

Biomarker-driven trials: Selection of patients with elevated ferroptosis markers

Future Directions

Phase 2/3 trials of brain-penetrant ferroptosis inhibitors
Combination trials of iron chelation + ferroptosis inhibition
Biomarker-driven patient selection trials
Gene therapy approaches for GPX4/FSP1 expression
Early intervention trials in prodromal PD

External Links

[Ferroptosis in Parkinson's Disease - Nature Reviews Neurology](https://pubmed.ncbi.nlm.nih.gov/39218077/)
[GPX4 and ferroptosis in PD - Journal of Neurochemistry](https://doi.org/10.1111/jnc.16123)
[FAIRPARK-II Trial Results](https://pubmed.ncbi.nlm.nih.gov/36449420/)
[Clinical Trials - Ferroptosis and Parkinson's Disease](https://clinicaltrials.gov/)

References

[Li et al., Ferroptosis in Parkinson disease — The iron-related degenerative disease (Nat Rev Neurol, 2024)](https://pubmed.ncbi.nlm.nih.gov/39218077/)

[Zhang et al., GPX4 and ferroptosis in Parkinson's disease (J Neurochem, 2024)](https://doi.org/10.1111/jnc.16123)

[Devos et al., Deferiprone in symptomatic Parkinsonian syndromes (Mov Disord, 2022)](https://pubmed.ncbi.nlm.nih.gov/35796012/)

[Moreau et al., Iron chelation with deferiprone in Parkinson's disease (Mov Disord, 2022)](https://pubmed.ncbi.nlm.nih.gov/36449420/)

[Devos et al., Conservative iron chelation for neurodegenerative diseases (Free Radic Biol Med, 2020)](https://pubmed.ncbi.nlm.nih.gov/31912279/)

[Masaldan et al., System Xc- in neurodegeneration (Cell Death Dis, 2023)](https://doi.org/10.1038/s41419-023-05890-1)

[Bader et al., System Xc- regulates neuronal survival and ferroptosis (Cell Mol Neurobiol, 2023)](https://doi.org/10.1007/s10571-023-01312-0)

[Chen et al., ACSL4 contributes to ferroptosis-induced dopaminergic neurodegeneration (Cell Discov, 2023)](https://doi.org/10.1038/s41421-023-00504-6)

[Cai et al., Nrf2 activation protects against ferroptosis in Parkinson's disease (Redox Biol, 2023)](https://doi.org/10.1016/j.redox.2023.102892)

[Zou et al., FSP1 protects dopaminergic neurons from ferroptosis in PD models (Mol Neurobiol, 2024)](https://doi.org/10.1007/s12035-024-06234-2)

[Anthonymuthu et al., Lipid peroxidation in Parkinson's disease (Antioxid Redox Signal, 2022)](https://doi.org/10.1089/ars.2022.0034)

[Do Van et al., Ferroptosis, a new mechanism of neuronal death in Parkinson's disease (Mov Disord, 2016)](https://pubmed.ncbi.nlm.nih.gov/26671615/)

[Ayton et al., Ferroptosis contributes to dopaminergic neuron loss in Parkinson's disease (Brain, 2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)

[Rembach et al., Clioquinol reduces Alzheimer's disease progression (J Alzheimers Dis, 2014)](https://pubmed.ncbi.nlm.nih.gov/24500047/)

[Skouta et al., Ferrostatins inhibit oxidative cell death and neural degeneration (J Am Chem Soc, 2014)](https://pubmed.ncbi.nlm.nih.gov/25330157/)

[Devos et al., Neurodegeneration in GPX4-deficient mouse models (Nat Neurosci, 2014)](https://pubmed.ncbi.nlm.nih.gov/24848240/)

[Conrad et al., Selenium and ferroptosis: insights into GPX4 regulation (Nat Rev Neurosci, 2016)](https://pubmed.ncbi.nlm.nih.gov/27339870/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — 0.73 · Target: ACSL4
[ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — 0.73 · Target: ACSL4
[Extracellular Matrix Stiffness Modulation](/hypothesis/h-725c62e9) — 0.53 · Target: PIEZO1
[Senescence-Induced Lipid Peroxidation Spreading](/hypothesis/h-7957bb2a) — 0.57 · Target: GPX4/SLC7A11
[Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — 0.60 · Target: ALOX12
[Mitochondrial SPM Synthesis Platform Engineering](/hypothesis/h-13bbfdc5) — 0.47 · Target: ALOX5
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Ferroptosis Therapy for Parkinson's Disease discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Ferroptosis Therapy for Parkinson's Disease

Ferroptosis Therapy for Parkinson's Disease

Ferroptosis Therapy for Parkinson's Disease

Pathway Diagram

Overview

Molecular Targets in Parkinson's Disease

GPX4 (Glutathione Peroxidase 4)

System Xc- (Cystine/Glutamate Antiporter)

ACSL4 (Acyl-CoA Synthetase Long-Chain Family Member 4)

FSP1 (Ferroptosis Suppressor Protein 1)

Nrf2 (Nuclear Factor Erythroid 2-Related Factor 2)

Therapeutic Approaches

1. GPX4-Targeted Therapies

Direct GPX4 Activators

GPX4 Substrate Enhancement

2. System Xc- Modulators

3. Direct Ferroptosis Inhibitors

Ferrostatins

Mechanism

4. Lipid Metabolism Modulators

5. Iron Chelation

6. Nrf2 Activators

Preclinical Evidence in Parkinson's Disease Models

In Vitro Evidence

In Vivo Evidence

Key Studies

Clinical Trials in Parkinson's Disease

Completed and Active Trials

FAIRPARK-II Trial Results

Ongoing Research

Biomarkers for Patient Selection

Ferroptosis Biomarkers

Patient Selection Criteria

Combination Strategies

Rationale for Combination Therapy

Promising Combinations

Cross-Linking to Related Pathways

Connected Mechanisms

Related Therapeutic Pages

Related Gene/Protein Pages

Challenges and Future Directions

Current Limitations

Emerging Strategies

Future Directions

See Also

External Links

References

Related Hypotheses

Pathway Diagram